F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Deal History & Licensing Activity
F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. is a life sciences. Over the past three years, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. has been involved in 11 licensing and acquisition transactions, with a primary focus on Antibodies (10 deals).
Deals (12mo)
4
Active Trials
0
Top Modality
Antibodies
Focus Area
Gastroenterology
F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| RVT-3101 / RO7790121 / afimkibart | Roche | Antibodies | Phase 2 | license | May 2026 |
| PRA023 (TL1A antibody) | Roche | Antibodies | Phase 2 | acquisition | May 2026 |
| MORI-057 (integrin α4β7 inhibitor) | Roche | Small Molecules | Phase 2 | license |
F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Pipeline Focus
Therapeutic areas and modalities where F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Gastroenterology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
About F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Licensing & Deal Activity
F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 11 deals over the past three years, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. include Gastroenterology (12 deals and trials), Cardiovascular (1 deal and trial), and Rare Disease (1 deal and trial). In terms of modality, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. has shown particular interest in antibodies, small molecules, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.